Encourage international talent to support cancer research
To keep discovering new cancer tests and treatments, we need to be able to recruit and retain the best talent and scientific leaders.
Being a global institution is part of what makes us successful and international talent is a key part of our research workforce. More than 35 per cent of our staff are from outside of the UK and we have staff from 67 different countries.
Recent modelling by the Royal Society showed that total upfront visa costs are up to seventeen times higher in the UK compared to the international average. It is simply not sustainable to have barriers of this magnitude in the way of attracting the best global talent when we are competing with the leading universities, institutes and companies across Europe and the USA.
Our ask: The UK needs a visa and immigration system which is competitive with other leading research nations. This is essential for us to continue being internationally leading and to compete with institutes and universities across the world. The Government should support the aim of recruiting international talent and leaders by reducing the costs for researchers, so the UK is competitive with comparable nations.
Advocacy blog posts
The Charity Research Support Fund: An overlooked, and neglected, lifeline for UK science
Ollie Richards, Advocacy Manager at the ICR, explores how a critical element of the Government's research funding – the Charity Research Support Fund – could be reformed to help support more specialist institutions and universities to do life-saving research.
100 days in – what do we need from the Government to enable cancer research to thrive?
We’re now 100 days into the new Government and the ICR’s Advocacy Manager, Ollie Richards, outlines what academic institutions need the Government to prioritise to help us on our mission to continue making the discoveries that defeat cancer.
Latest ICR News
Blood test could spare men with advanced prostate cancer from futile chemotherapy
New research has identified a way to predict resistance to a cancer drug commonly used to treat advanced prostate cancer.
ICR researchers to contribute to £13.7m brain tumour research consortium
The NIHR has announced a £13.7 million investment into research to develop new brain tumour treatments in the UK. The funding will establish the NIHR Brain Tumour Research Consortium – a national partnership uniting hospitals, universities, cancer centres and charities, along with patients. This is a coordinated UK-wide effort, which will involve the ICR's scientists, aims to transform brain cancer treatment.
New structural insights reveal molecular details of a key step in cell cycle control
In a major advance for molecular biology and cancer research, scientists have uncovered the molecular mechanisms that control a key step during the activation of cyclin-dependent kinases (CDKs) – the master regulators of cell division.